The Supreme Court will on Monday deliver its verdict on the landmark patent case involving Swiss drugmaker Novartis AG,which has led a seven-year long legal battle demanding patent protection for its cancer medicine Glivec.
Novartis was refused patent on Glivec on the ground that it is not a new medicine but an amended version of a known compound.
The ruling will decide a battle between public health and affordability on one hand against research and innovation on the other,as the apex court delivers its final word on the interpretation of a relevant patent law.
The case pitches the battle between big pharma companies that want protection of patent and thus their investments,against others,which claim they should be allowed to continue producing cheaper generic versions of life-saving medicines. The judgment will be crucial for it will give an indication on what is patentable.